Why Gilead Sciences Stock Is Jumping Today
Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year financial results following market close on Tuesday.
Gilead Sciences Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a three-day winning streak.
Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Feb 11, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participant
Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.27% to 6,051.97 and Dow Jones Industrial Average falling 0.
Why Gilead Sciences (GILD) Stock Is Trading Up Today
What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue,
Gilead got D'Arcy Carden
For now, this iteration of The Handmaid’s Tale is set to begin its final installment April 8, and for better or worse, D’Arcy ...
STAT2d
Gilead’s short-term win threatens the future of pharmaceutical public-private partnerships
The settlement in U.S. v. Gilead could disturb the model of public-private partnership that sustains many of the United ...
Gilead provides upbeat 2025 forecast, shares rise 4%
Gilead Sciences posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst ...
Fierce Pharma2d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
How key drugs boosted Gilead — and how the Inflation Reduction Act could deliver a billion-dollar hit
Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...
Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
‘The Handmaid’s Tale’ Reveals Final Season Release Date and First Look: The Red Revolution Is Here
The red-cloaked army is coming for Gilead in a the first look at the Hulu hit's April return. The Handmaid’s Tale has revealed its release date and a first-look teaser for the highly anticipated final ...
Gilead price target raised to $116 from $109 at BofA
BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...